![](/wp-content/themes/yootheme/cache/16/Ohio-163cb46e.jpeg)
Local Cdiff information for Ohio
Ohio
Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Ohio.
Local Cdiff information for Ohio
Ohio
Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Ohio.
![](/wp-content/themes/yootheme/cache/16/Ohio-163cb46e.jpeg)
Providers
Dr. Edmond Blades, MD
North Ohio Gastroenterology
30701 Clemens Road
Westlake, 44145
(440) 617-1212
FMT Provider: Yes
Dr. Michelle T. Hecker, MD
Infectious Disease Specialist
MetroHealth Medical Center
2500 MetroHealth Drive
Cleveland, 44109
(216) 778-8305
FMT Provider: Yes
Dr. Bret Lashner, MD
Cleveland Clinic Main Campus
9500 Euclid Avenue
Cleveland, 44195
(216) 444-7000
FMT Provider: Yes
Dr. Nikole Scalera, MD
Summa Akron City Hospital
75 Arch Street
Suite 506, Suite 104
Akron, 44304
(330) 375-3894
FMT Provider: Yes
Abhishek Deshpande, MD, PhD
Cleveland Clinic
9500 Euclid Avenue
Cleveland, OH 44195
(216) 444-4885
Regulation
C. diff Infections
Total Reported Cases: 3432
Hospital Onset: 3432
Community Onset: Not reported
Related Deaths: Not reported
Available Reports
State Reporting Laws
Data Submission Required: Yes
Data Publicly Available: Yes
Data Validated: No
Facility-specific Data Publicly Reported: Yes
LTC Facility Submission Required: No
LTC Facility Data Publicly Reported: No
Law/Regulation: Rule 3701-14-04 of the administrative code
State Contact
Marika C. Mohr, MS, RN, CIC
Infectious Disease Control Consultant
Ohio Department of Health
Bureau of Infectious Diseases, Outbreak Response and Bioterrorism Investigation Team
35 East Chestnut Street, 6 FL
Columbus, 43215
(614) 466-9067
(614) 564-2456
CLINICAL TRIALS
Evaluation of GeoHAI Implementation
Official Title: GeoHAI Implementation in IP Workflow
Trial No. NCT05612672
Type: Interventional
Recruitment: Recruiting
Sponsor: Ohio State University
Contact: Ohio State University Office of Responsible Research Practices
800-678-6251
Gender: All
Age: 18 Years and older
OpTION
Official Title: CSP #596 – Optimal Treatment for Recurrent Clostridium Difficile Infection
Trial No. NCT02667418
Type: Interventional
Recruitment: Recruiting
Sponsor: VA Office of Research and Development
Contact: Michelle Johnson
(708) 202-8387 ext 27001
Gender: All
Age: 18 Years and older
Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection (FMT)
Official Title: Fecal Microbiota Transplantation (FMT) for Recurrent or Refractory C. Difficile Infection (CDI) in Pediatric and Young Adult Patients
Trial No. NCT02134392
Type: Interventional
Recruitment: Recruiting
Sponsor: Jonathan Gisser
Contact: Ling Fan, MPH
614-722-3412
Gender: All
Age: 2 Years to 21 Years
ROAR
Official Title: REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
Trial No. NCT05835219
Type: Observational
Recruitment: Recruiting
Sponsor: Ferring Pharmaceuticals
Contact: Global Clinical Compliance
833-548-1402
Gender: All
Age: 18 Years and older
To Understand the Safety and Effects of a C. Difficile Vaccine
Official Title: A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, Immunogenicity, and Immunopersistence of a Clostridioides Difficile Vaccine
Trial No. NCT05835219
Type: Interventional
Recruitment: Recruiting
Sponsor: Pfizer
Contact: Pfizer CT.gov Call Center
Gender: All
Age: 65 Years and older
RESTORATiVE303
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
Gender: All
Age: 12 Years and older
Vedanta Biosciences has teamed up with Science37 to provide a site-less, decentralized approach. This means the study can be done remotely and the product comes to you, in your home. This allows applicants who are not near a study site or unable to travel to participate and receive treatment. You can sign up for the decentralized study here.